Dextropac 25 IV IV Infusion
Dextrose 25%
25gm/100ml
Orion Pharma Ltd.
| Pack size | 100ml, 250ml ampoule |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 48.14,73.22 AED |
Indications
Dextropac 25 IV IV Infusion is used for:
Parenteral Nutrition and Hydration, Hypoglycemia, Hyperkalaemia, Energy malnutrition
Adult Dose
Intravenous
Hypoglycaemia
Adult: 10-25 g (40-100 ml of 25% solution). Doses may be repeated in severe cases.
Hyperkalaemia
Adult: 25-50 g combined with 10 units of regular insulin, administered over 30-60 minutes; may repeat if necessary.
Alternatively, 25 g combined with 5-10 units of regular insulin infused over 5 minutes; may repeat if necessary.
Child Dose
Intravenous
Hypoglycaemia
Child: <6 mth: 0.25-0.5 g/kg/dose;
>6 mth: 0.5-1 g/kg/dose. Doses may be repeated in severe cases. Max: 25 g/dose.
Hyperkalaemia
Child: and infants: 0.5-1 g/kg (using 25% or 50% solution) combined with regular insulin (1 unit for every 4-5 g dextrose given); infuse over 2 hr, may repeat if necessary.
Renal Dose
Administration
IV Administration
Hypertonic dextrose solutions are preferably administered via an IV catheter placed into a large central vein
If hypertonic (10%) dextrose solutions are administered peripherally, use a large arm vein, if possible, alternate injection site daily
Except in the emergency treatment of severe hypoglycemia, higher concentrations of dextrose injections (e.g., 20% and higher) should be administered via central veins and only after appropriate dilution
When used for the emergency treatment of hypoglycemia, hypertonic dextrose injections may be administered slowly via a peripheral vein
Include final filter to administration protocol and visually inspect container
Contra Indications
Known allergy to corn or corn products.
Diabetic coma with hyperglycaemia.
Use of hypertonic solutions in patients with intracranial or intraspinal haemorrhage.
Patients with delirium tremens and dehydration.
Anuria, hepatic coma, or glucose-galactose malabsorption syndrome.
Precautions
Overt or known subclinical DM.
Patients with carbohydrate intolerance.
IV admin of dextrose may result in hypokalaemia, hypophosphataemia and hypomagnesemia.
Prolonged infusion of isotonic dextrose solutions may cause water intoxication.
Production of insulin may be adversely affected by prolonged parenteral nutrition with dextrose solutions.
Rapid admin of hypertonic dextrose solutions may result in hyperglycaemia and hyperosmolar syndrome.
Hypertonic solutions (>10%) may cause thrombosis when infused through peripheral veins; best to infuse through a central venous catheter.
Increased serum osmolality and possible intracerebral hemorrhage may occur from rapid or excessive dextrose administration.
Parenteral nutrition associated with liver disease; increased risk in patients who receive parenteral nutrition for extended periods of time, especially preterm infants.
Caution when used in very low birth weight infants.
Abrupt withdrawal may lead to rebound hypoglycaemia.
Risk of thrombosis when hypertonic (>10%) solutions are administered through peripheral veins.
Caution when used parenterally in pregnant women.
Monitoring Parameters
Monitor for signs of mental confusion or loss of consciousness.
Monitor blood and urinary glucose regularly.
Monitor changes in fluid balance, electrolyte concentrations, and acid-base balance during prolonged use.
Monitor glucose levels and for possible hyperglycemia when treating pediatric patients.
Monitor blood glucose and administer insulin as needed.
Pregnancy-Lactation
Pregnancy Category: C
Maternal and fetal hyperglycemia may occur during labor and delivery; monitor
Lactation: Excretion in milk unknown; use with caution
Interactions
Adverse Effects
Side effects of Dextrose 25% :
Frequency Not Defined
Hyperosmolarity
Edema
Venous thrombosis
Tachypnea
Fever
Hypermolar syndrome
Hypervolemia
Phlebitis
Diarrhea
Polydipsia
Pulmonary edema
Cerebral hemorrhage
Mental confusion, unconsciousness
Cerebral ischemia
Hypophosphatemia
Hypomagnesemia
Hyperglycemia
Injection site extravasation
Tissue necrosis
Mechanism of Action
Dextrose is a monosaccharide that is used as a source of calories and water for hydration. It helps to reduce loss of body protein and nitrogen. It also promotes glycogen deposition in the liver. When used with insulin, it stimulates the uptake of potassium by cells, especially in muscle tissue, thus lowering serum potassium levels.
Note
Dextropac 25 IV 25gm/100ml IV Infusion manufactured by Orion Pharma Ltd.. Its generic name is Dextrose 25%. Dextropac 25 IV is availble in Bangladesh.
Farmaco BD drug index information on Dextropac 25 IV IV Infusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.